SPOTLIGHT -
Slideshow
Author(s):
A novel protocol lights the way for a promising treatment for bipolar depression.
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.
FDA Approves Risperidone Extended-Release Injectable Suspension
Blue Light, Depression, and Bipolar Disorder
Primary End Point of Phase 3 Trial Met: BXCL501 for Agitation Associated With Bipolar Disorders or Schizophrenia
Four Myths About Lamotrigine
Hepatitis-C Virus Found to Be Associated With Schizophrenia and Bipolar Disorder
BXCL501 for Agitation Associated With Bipolar Disorders or Schizophrenia: Positive Pre-sNDA Meeting With FDA